MEDICINOVA, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
MEDICINOVA, INC. (MNOV) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $842.01 thousand as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-10
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $842.01K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $938.85K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.50M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.53M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $842.01K 10-K · filed 2026-03-10 | |
| 2024-12-31 | $938.85K 10-K · filed 2026-03-10 | |
| 2023-12-31 | $1.50M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $1.53M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $1.60M 10-K/A · filed 2023-03-28 | $1.60B 10-K · filed 2022-02-16 |
| 2020-12-31 | $2.90B 10-K · filed 2022-02-16 | |
| 2019-12-31 | $3.12B 10-K · filed 2021-02-19 | |
| 2018-12-31 | $3.12M 10-K · filed 2020-02-13 | $3.92M 10-K · filed 2019-02-13 |
| 2017-12-31 | $3.92M 10-K · filed 2020-02-13 | $2.58M 10-K · filed 2018-02-13 |
| 2016-12-31 | $2.38M 10-K · filed 2018-02-13 | |
| 2015-12-31 | $2.62M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $2.15M 10-K · filed 2017-02-14 | |
| 2013-12-31 | $1.76M 10-K · filed 2015-03-12 | |
| 2012-12-31 | $1.86M 10-K · filed 2014-03-27 | $570.00K 10-K · filed 2013-03-28 |
| 2011-12-31 | $395.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |